Thursday, July 25, 2024
HomeBusinessU.S. lawmakers to investigate approval, pricing of Alzheimer's drug from Biogen By...

U.S. lawmakers to investigate approval, pricing of Alzheimer’s drug from Biogen By Reuters


Related stories

Why It’s Important for Teachers to Teach Social and Emotional Skills

Academic knowledge alone is not enough to prepare students...

How Religion Supports and Shields Children’s Mental Health

In the UK today, many parents and foster carers...

The Key Benefits of Ergonomic Loupes in Dentistry and Surgery

In the demanding fields of dentistry and surgery, precision...

Industry-Specific Safety Glasses: Choosing the Right Pair for Your Job

Workplace safety is a paramount concern across various industries....

10 Reasons You Should Try To Be More Likeable

Being likeable has a deep impact on both personal...


© Reuters. FILE PHOTO: A sign marks a Biogen facility, some of whose employees have tested positive for the coronavirus after attending a meeting in Boston, in Cambridge, Massachusetts, U.S., March 9, 2020. REUTERS/Brian Snyder

(Reuters) -U.S. lawmakers on Friday announced an investigation into the approval and pricing of Biogen Inc (NASDAQ:)’s Alzheimer’s drug, Aduhelm, amid concerns over its steep price and doubts if the clinical evidence proves the drug works.

The drug, which has a list price of $56,000 per year, was approved by the U.S. regulators as the first treatment to attack a likely cause of Alzheimer’s on June 7.

“We have serious concerns about the steep price of Biogen’s new Alzheimer’s drug Aduhelm and the process that led to its approval despite questions about the drug’s clinical benefit,” House Committee on Oversight and Reform said in a statement.

The investigation has been announced by Rep. Carolyn Maloney, chairwoman of the Committee on Oversight and Reform, and Rep. Frank Pallone, Jr., Chairman of the Committee on Energy and Commerce.

Biogen said it will “of course cooperate with any inquiry we may receive from these committees,” in response to a Reuters request for comment.

At $56,000 a year, the Kaiser Family Foundation estimates that Medicare could spend $57 billion or more per year on Aduhelm, which is more than Medicare Part B spends on all other drugs combined, the House Committee said.

Health insurers and the Medicare program will bear most of the cost of the drug, whose price will vary based on dosage and discounts.

The Food and Drug Administration (FDA) approved the drug – despite strong objection from its own expert advisory panel – for all patients with Alzheimer’s, although it has only been tested for patients in the early stages of the disease.

See also  The Role of Efficient Payment Methods in the Modern World

Three of the 11 members of FDA’s independent advisory panel have resigned in protest over the agency’s decision.

Shares of the drugmaker were down nearly 1% in after-market trading.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.


Source link

Bellie Brown
Bellie Brown
Hi my lovely readers, I am Bellie brown editor and writer of I write blogs on various niches such as business, technology, lifestyle., health, entertainment, etc as well as manage the daily reports of the website. I am very addicted to my work which makes me keen on reading and writing on the very latest and trending topics. One can check my more writings by visiting

Latest stories